Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. The company's products are used for medical surgery and neurotechnology (60% of 2024 revenues), which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery (40% of 2024 revenues), which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| SYK | STRYKER CORP | 2025-10-16 18:37:50 | 366.12 | -3.13 | -0.85 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYK | 0000310764 | STRYKER CORP | US8636671013 | 5493002F0SC4JTBU5137 | 381239739 | NYSE | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | MI | 1941 STRYKER WAY | PORTAGE | MI | 49002 | UNITED STATES | US | 2693852600 | 1941 STRYKER WAY, PORTAGE, MI, 49002 | 1941 STRYKER WAY, PORTAGE, MI, 49002 | — | Health technology | 1941 | Kevin A. Lobo | 53,000 | http://stryker.com | 123,147,898,554 | — | 382,307,298 | Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. The company's products are used for medical surgery and neurotechnology (60% of 2024 revenues), which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery (40% of 2024 revenues), which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States. | 2025-10-10 19:04:35 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 123,147,898,554 | 13,424,995,965 | 12.2354 | 381,579,123 | 1,315,087 | 0.3458 |
| 2023 | 109,722,902,589 | 38,757,739,736 | 54.6152 | 380,264,036 | 1,432,787 | 0.3782 |
| 2022 | 70,965,162,853 | -20,977,311,510 | -22.8157 | 378,831,249 | 1,286,563 | 0.3408 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| J. Andrew Pierce | Group President | 2024 | 750,000 | — | 2,541,612 | 917,325 | 211,695 | 6,759,339 |
| Spencer S. Stiles | Group President | 2024 | 750,000 | — | 2,541,612 | 917,325 | 211,695 | 6,759,339 |
| Kevin A. Lobo | Chair, President, Chief Executive Officer | 2024 | 1,441,667 | — | 8,699,604 | 2,936,250 | 897,865 | 21,979,369 |
| Glenn S. Boehnlein | Chief Financial Officer, Vice President | 2024 | 793,334 | — | 2,723,253 | 1,080,000 | 237,747 | 7,339,754 |
| Viju S. Menon | Group President | 2024 | 645,833 | — | 1,573,770 | 745,875 | 176,229 | 4,589,506 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 53,000 |
| 2023 | 52,000 |
| 2022 | 51,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 22,595,000,000 | 20,498,000,000 | 18,449,000,000 |
| Cost Of Revenue | 8,155,000,000 | 7,440,000,000 | 6,871,000,000 |
| Gross Profit | 14,440,000,000 | 13,058,000,000 | 11,578,000,000 |
| Research And Development Expenses | 1,466,000,000 | 1,388,000,000 | 1,454,000,000 |
| General And Administrative Expenses | 7,685,000,000 | 7,129,000,000 | 6,455,000,000 |
| Operating Expenses | 10,751,000,000 | 9,170,000,000 | 8,737,000,000 |
| Operating Income | 3,689,000,000 | 3,888,000,000 | 2,841,000,000 |
| Net Income | 2,993,000,000 | 3,165,000,000 | 2,358,000,000 |
| Earnings Per Share Basic | 7.86 | 8.34 | 6.23 |
| Earnings Per Share Diluted | 7.76 | 8.25 | 6.17 |
| Weighted Average Shares Outstanding Basic | 381,000,000 | 379,600,000 | 378,200,000 |
| Weighted Average Shares Outstanding Diluted | 385,600,000 | 383,700,000 | 382,200,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 3,652,000,000 | 2,971,000,000 | 1,844,000,000 |
| Marketable Securities Current | 91,000,000 | 82,000,000 | 84,000,000 |
| Accounts Receivable | 3,987,000,000 | 3,765,000,000 | 3,565,000,000 |
| Inventories | 4,774,000,000 | 4,843,000,000 | 3,995,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,593,000,000 | 857,000,000 | 787,000,000 |
| Total Assets Current | 14,847,000,000 | 12,518,000,000 | 10,275,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,448,000,000 | 3,215,000,000 | 2,970,000,000 |
| Other Assets Non Current | 2,684,000,000 | 2,673,000,000 | 2,464,000,000 |
| Total Assets Non Current | 28,124,000,000 | 27,394,000,000 | 26,609,000,000 |
| Total Assets | 42,971,000,000 | 39,912,000,000 | 36,884,000,000 |
| Accounts Payable | 1,679,000,000 | 1,517,000,000 | 1,413,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 1,409,000,000 | 2,094,000,000 | 1,191,000,000 |
| Other Liabilities Current | 2,266,000,000 | 1,928,000,000 | 1,744,000,000 |
| Total Liabilities Current | 7,616,000,000 | 7,921,000,000 | 6,303,000,000 |
| Long Term Debt | 12,188,000,000 | 10,901,000,000 | 11,857,000,000 |
| Other Liabilities Non Current | 2,184,000,000 | 1,930,000,000 | 1,467,000,000 |
| Total Liabilities Non Current | 14,721,000,000 | 13,398,000,000 | 13,965,000,000 |
| Total Liabilities | 22,337,000,000 | 21,319,000,000 | 20,268,000,000 |
| Common Stock | 38,000,000 | 38,000,000 | 38,000,000 |
| Retained Earnings | 18,528,000,000 | 16,771,000,000 | 14,765,000,000 |
| Accumulated Other Comprehensive Income | -293,000,000 | -416,000,000 | -221,000,000 |
| Total Shareholders Equity | 20,634,000,000 | 18,593,000,000 | 16,616,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 623,000,000 | 635,000,000 | 627,000,000 |
| Share Based Compensation Expense | 229,000,000 | 205,000,000 | 168,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 321,000,000 | 175,000,000 | 579,000,000 |
| Change In Inventories | 206,000,000 | 797,000,000 | 762,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 192,000,000 | 77,000,000 | 290,000,000 |
| Change In Other Liabilities | 306,000,000 | 134,000,000 | 107,000,000 |
| Cash From Operating Activities | 4,242,000,000 | 3,711,000,000 | 2,624,000,000 |
| Purchases Of Marketable Securities | 58,000,000 | 52,000,000 | 52,000,000 |
| Sales Of Marketable Securities | 49,000,000 | 54,000,000 | 43,000,000 |
| Acquisition Of Property Plant And Equipment | 755,000,000 | 575,000,000 | 588,000,000 |
| Acquisition Of Business | 1,628,000,000 | 390,000,000 | 2,563,000,000 |
| Other Investing Activities | -43,000,000 | -1,000,000 | -39,000,000 |
| Cash From Investing Activities | -3,000,000,000 | -962,000,000 | -2,924,000,000 |
| Tax Withholding For Share Based Compensation | 195,000,000 | 155,000,000 | 122,000,000 |
| Payments Of Dividends | 1,219,000,000 | 1,139,000,000 | 1,051,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 3,011,000,000 | 1,241,000,000 | 1,500,000,000 |
| Repayment Of Long Term Debt | 2,039,000,000 | 2,058,000,000 | 653,000,000 |
| Other Financing Activities | -51,000,000 | -23,000,000 | -48,000,000 |
| Cash From Financing Activities | -525,000,000 | -1,594,000,000 | -749,000,000 |
| Change In Cash | 681,000,000 | 1,127,000,000 | -1,100,000,000 |
| Cash At End Of Period | 3,652,000,000 | 2,971,000,000 | 1,844,000,000 |
| Income Taxes Paid | 989,000,000 | 693,000,000 | 505,000,000 |
| Interest Paid | 396,000,000 | 356,000,000 | 324,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 7.86 | 8.34 | 6.23 |
| Price To Earnings Ratio | 45.8079 | 35.9065 | 39.244 |
| Earnings Growth Rate | -5.7554 | 33.8684 | 17.7694 |
| Price Earnings To Growth Ratio | -7.9591 | 1.0602 | 2.2085 |
| Book Value Per Share | 54.1575 | 48.9805 | 43.9344 |
| Price To Book Ratio | 6.6482 | 6.1139 | 5.5649 |
| Ebitda | 5,001,000,000 | 4,849,000,000 | 3,827,000,000 |
| Enterprise Value | 147,124,050,000 | 123,699,016,000 | 103,670,118,000 |
| Dividend Yield | 0.0089 | 0.01 | 0.0114 |
| Dividend Payout Ratio | 0.4073 | 0.3599 | 0.4457 |
| Debt To Equity Ratio | 0.659 | 0.6989 | 0.7853 |
| Capital Expenditures | 856,000,000 | 880,000,000 | 764,000,000 |
| Free Cash Flow | 3,386,000,000 | 2,831,000,000 | 1,860,000,000 |
| Return On Equity | 0.1451 | 0.1702 | 0.1419 |
| One Year Beta | 0.5775 | 0.8335 | 1.0033 |
| Three Year Beta | 0.8941 | 0.9811 | 1.1054 |
| Five Year Beta | 1.0458 | 1.0724 | 1.0725 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Menon Viju | Group President | 2025-08-25 | 500 | D | 12,511 |
| Fletcher Robert S | VP, Chief Legal Officer | 2025-08-20 | 1,785 | D | 10,457 |
| STRYKER RONDA E | Director | 2025-08-06 | 34,911 | D | 3,387,197 |
| STRYKER RONDA E | Director | 2025-08-06 | 76,200 | D | 3,310,997 |
| STRYKER RONDA E | Director | 2025-08-06 | 50,016 | D | 3,260,981 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel S Sullivan | Senator | 2023-07-26 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| Daniel S Sullivan | Senator | 2022-12-21 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| David A Perdue , Jr | Senator | 2021-05-02 | Sale (Full) | 2020-04-14 | Joint | $1,001 - $15,000 |
| David A Perdue , Jr | Senator | 2020-05-08 | Sale (Full) | 2020-04-14 | Joint | $1,001 - $15,000 |
| David A Perdue , Jr | Senator | 2019-11-05 | Sale (Partial) | 2019-09-30 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H. Kean | 2025-10-14 | NJ07 | Sale (Partial) | 2025-09-12 | — | $15,001 - $50,000 |
| Thomas H. Kean | 2025-09-18 | NJ07 | Sale (Partial) | 2025-08-25 | — | $1,001 - $15,000 |
| Thomas H. Kean | 2025-08-20 | NJ07 | Sale (Partial) | 2025-07-31 | — | $15,001 - $50,000 |
| Thomas H. Kean | 2025-07-16 | NJ07 | Sale (Partial) | 2025-06-26 | — | $15,001 - $50,000 |
| Jefferson Shreve | 2025-06-22 | IN06 | Sale | 2025-05-12 | — | $50,001 - $100,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bill Few Associates, Inc. | 2025-09-30 | 919,369 | 2,487 | 369.6699 |
| Carnegie Investment Counsel | 2025-09-30 | 77,899,140 | 210,726 | 369.6703 |
| AMI INVESTMENT MANAGEMENT INC | 2025-09-30 | 4,090,769 | 11,066 | 369.6701 |
| Columbus Macro, LLC | 2025-09-30 | 5,085,512 | 13,757 | 369.6672 |
| GREENWOOD CAPITAL ASSOCIATES LLC | 2025-09-30 | 6,677,587 | 18,064 | 369.6627 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Jensen Quality Growth Fund Inc | 2025-08-31 | Y Shares | JENYX | 990,000 | 387,495,900 | 6.685 |
| Jensen Quality Growth Fund Inc | 2025-08-31 | R Shares | JENRX | 990,000 | 387,495,900 | 6.685 |
| Jensen Quality Growth Fund Inc | 2025-08-31 | I Shares | JENIX | 990,000 | 387,495,900 | 6.685 |
| Jensen Quality Growth Fund Inc | 2025-08-31 | J Shares | JENSX | 990,000 | 387,495,900 | 6.685 |
| Strategic Trust | 2025-08-31 | RUNNING OAK EFFICIENT GROWTH ETF | RUNN | 17,309 | 6,774,915.69 | 1.7848 |